Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth G Saag

Showing results (31-40 of 374) with videos related to

Pageof 38
Sort By:
The Orthopedic Clinics of North America|April 3, 2013
Osteoporosis diagnosis and medical treatmentAmy H Warriner, Kenneth G Saag
The Journal of Rheumatology|August 1, 2025
Denosumab for Osteoporosis Treatment in Rheumatic Diseases: What Do We Know 15 Years Post Approval?Stanley B Cohen, Kenneth G Saag
Nature Clinical Practice. Rheumatology|August 26, 2006
Is febuxostat a more effective treatment for hyperuricemia and gout than allopurinol?W Winn Chatham, Kenneth G Saag
Current Rheumatology Reports|May 28, 2005
Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?Ted R Mikuls, Kenneth G Saag
Current Osteoporosis Reports|May 26, 2011
Is two better than one? Combining antiresorptive and anabolic osteoporosis medicationsNicole C Wright, Kenneth G Saag
Current Osteoporosis Reports|February 27, 2007
Prevention and treatment of glucocorticoid-induced osteoporosisJeffrey R Curtis, Kenneth G Saag
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Improving the quality of clinical care for patients with osteoporosisKatri P Palonen, Kenneth G Saag
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 31, 2008
Management of hyperuricemia and gout in CKDAngelo L Gaffo, Kenneth G Saag
Current Opinion in Endocrinology, Diabetes, and Obesity|January 29, 2014
Glucocorticoid-related bone changes from endogenous or exogenous glucocorticoidsAmy H Warriner, Kenneth G Saag
Current Rheumatology Reports|March 29, 2012
From fracture risk prediction to evaluating fracture patterns: recent advances in the epidemiology of osteoporosisNicole C Wright, Kenneth G Saag
Pageof 38

Showing results (31-40 of 374) with videos related to

Sort By:
Pageof 38
The Orthopedic Clinics of North America|April 3, 2013
Osteoporosis diagnosis and medical treatmentAmy H Warriner, Kenneth G Saag
The Journal of Rheumatology|August 1, 2025
Denosumab for Osteoporosis Treatment in Rheumatic Diseases: What Do We Know 15 Years Post Approval?Stanley B Cohen, Kenneth G Saag
Nature Clinical Practice. Rheumatology|August 26, 2006
Is febuxostat a more effective treatment for hyperuricemia and gout than allopurinol?W Winn Chatham, Kenneth G Saag
Current Rheumatology Reports|May 28, 2005
Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?Ted R Mikuls, Kenneth G Saag
Current Osteoporosis Reports|May 26, 2011
Is two better than one? Combining antiresorptive and anabolic osteoporosis medicationsNicole C Wright, Kenneth G Saag
Current Osteoporosis Reports|February 27, 2007
Prevention and treatment of glucocorticoid-induced osteoporosisJeffrey R Curtis, Kenneth G Saag
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Improving the quality of clinical care for patients with osteoporosisKatri P Palonen, Kenneth G Saag
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 31, 2008
Management of hyperuricemia and gout in CKDAngelo L Gaffo, Kenneth G Saag
Current Opinion in Endocrinology, Diabetes, and Obesity|January 29, 2014
Glucocorticoid-related bone changes from endogenous or exogenous glucocorticoidsAmy H Warriner, Kenneth G Saag
Current Rheumatology Reports|March 29, 2012
From fracture risk prediction to evaluating fracture patterns: recent advances in the epidemiology of osteoporosisNicole C Wright, Kenneth G Saag
Pageof 38